Update survival analysis from a multicenter, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).

Antonio Avallone,Guglielmo Nasti,Gerardo Rosati,Chiara Carlomagno,Lucrezia Silvestro,Antonino Cassata,Carmen Romano,Vincenza Granata,Alfonso De Stefano,Salvatore Tafuto,F Bianco,Valeria Vicario,Domenico Bilancia,Secondo Lastoria,Antonella Petrillo,Francesco Izzo,Ciro Gallo,Paolo Delrio,Alfredo Budillon,Maria Carmela Piccirillo

Update survival analysis from a multicenter, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).

2018

3562Background: Bevacizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, approved in combination with chemotherapy in the treatment of mCRC. It has been hypoth...

Keywords:

Bevacizumab
Cancer research
Phases of clinical research
Physical therapy
FOLFOX
Colorectal cancer
Medicine
Oncology
Chemotherapy
Survival analysis
Internal medicine
Pathology
Monoclonal antibody
Growth factor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations